Clinigen Group plc Change of Joint Broker (8046T)
January 13 2017 - 4:00AM
UK Regulatory
TIDMCLIN
RNS Number : 8046T
Clinigen Group plc
13 January 2017
13 January 2017
Change of Joint Broker
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the
global pharmaceutical and services group, announces that it has
appointed RBC Capital Markets to act as its Joint Broker with
immediate effect. Numis Securities Limited continues to act as
Nominated Adviser and Joint Broker to the Company.
-Ends-
Contact Details
Clinigen Group plc Tel: +44 (0) 1283
495 010
Shaun Chilton, Group Chief
Executive Officer
Martin Abell, Group Chief Financial
Officer
Matt Parrish, Head of Investor
Relations
Numis Securities Limited Tel: +44 (0) 20
7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Tom Ballard
(Corporate Broking)
RBC Capital Markets Tel: +44 (0) 20
7653 4000
Marcus Jackson / Elliot Thomas
/ Jack Wood
Instinctif Partners (media Tel: +44 (0) 20
relations) 7457 2020
Adrian Duffield / Melanie Toyne-Sewell Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing access to medicines. Its mission is to deliver the right
medicine to the right patient at the right time.
The Group consists of five synergistic businesses focused in
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines.
Clinigen Clinical Trial Services is the global market leader in
the management and supply of commercial medicines for clinical
trials.
The Group is also the trusted global leader in ethically
sourcing and supplying unlicensed medicines to hospital pharmacists
and physicians for patients with a high unmet need, through three
of its divisions: Idis Managed Access runs early access programs
for innovative new medicines. Idis Global Access and Link
Healthcare work directly with healthcare professionals to enable
compliant access to unlicensed medicines on a global basis and
niche essential licensed and generic medicines across Australasia,
Africa and Asia (AAA region).
Clinigen Specialty Pharmaceuticals acquires global rights,
revitalises and markets its own portfolio of niche hospital
commercial products.
For more information, please visit www.clinigengroup.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
APPBMMBTMBABBRR
(END) Dow Jones Newswires
January 13, 2017 05:00 ET (10:00 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024